Regarding the pathophysiology and risk factors of acute ischemic stroke, all of the following statements are correct EXCEPT:

Explanation

## Pathophysiology & Risk Factors in Ischemic Stroke **Key Point:** Understanding modifiable and non-modifiable risk factors is essential for stroke prevention. Not all risk factors with epidemiologic association have proven therapeutic benefit — and not all interventions that seem logical have been validated in clinical trials [Harrison 21e, Ch 445]. ### Stroke Risk Factors: Evidence Summary | Risk Factor | Relative Risk | Intervention | Proven Benefit | |-------------|---------------|--------------|----------------| | **Atrial fibrillation** | ~5-fold | Anticoagulation (warfarin, DOACs) | Yes (~65% RRR in primary prevention) | | **Hypertension** | 2–4 fold | BP reduction | Yes (~30% RRR per 10 mmHg systolic) | | **Diabetes** | 2–4 fold | Tight glycemic control (HbA1c <6.5%) | **NOT proven / Mixed evidence** | | **Elevated homocysteine** | 1.5–2 fold | Folic acid, B12, B6 | No (NORVIT, HOPE-2 negative) | ### Why Option A is INCORRECT (the EXCEPT answer) Option A states that **tight glycemic control (HbA1c < 6.5%) reduces stroke incidence in both type 1 and type 2 diabetes** — this is **overstated and not supported by major clinical trials**: - **ACCORD trial (Action to Control Cardiovascular Risk in Diabetes):** Intensive glucose lowering (HbA1c target < 6.0%) in type 2 diabetes did **NOT** reduce macrovascular events including stroke, and was associated with **increased all-cause mortality** and hypoglycemia. - **ADVANCE trial:** Moderate glycemic control showed modest benefit in microvascular outcomes but not clearly in stroke. - **Type 1 diabetes:** Evidence for macrovascular (stroke) benefit from tight glycemic control is even less established; the DCCT/EDIC trial showed benefit primarily for microvascular complications. - **Current guidelines (ADA, AHA/ASA):** Recommend HbA1c ~7% (not <6.5%) for most patients, balancing cardiovascular risk with hypoglycemia risk. **High-Yield:** The claim that tight glycemic control (HbA1c <6.5%) reduces stroke incidence in **both** type 1 and type 2 diabetes is factually incorrect based on current evidence. ### Why Options B, C, and D are CORRECT - **Option B (Hypertension):** Hypertension is the single most important modifiable stroke risk factor. Meta-analyses confirm ~30% relative risk reduction in stroke per 10 mmHg systolic BP reduction (Lawes et al., Lancet 2004). - **Option C (Atrial fibrillation):** AF increases stroke risk ~5-fold. Anticoagulation (warfarin or DOACs) reduces this risk by approximately 64–65% in primary prevention (Hart et al., Ann Intern Med 2007). - **Option D (Homocysteine):** Elevated homocysteine is an **independent risk marker** for ischemic stroke (observational data). While homocysteine-lowering therapy (folic acid + B12) has NOT been proven to reduce stroke recurrence (NORVIT, HOPE-2 trials), the statement in Option D says it "has been proven to reduce stroke recurrence" — which is FALSE. However, in the context of this EXCEPT question, Option D is also a candidate. The **stronger and more clearly incorrect** statement is Option A, which makes a definitive claim about tight glycemic control reducing stroke incidence that is directly contradicted by the ACCORD trial. **Clinical Pearl:** This is a classic example of the difference between a risk factor (diabetes) and a proven modifiable intervention (tight glycemic control). Diabetes increases stroke risk, but aggressive glucose lowering to HbA1c <6.5% has not been shown to reduce stroke and may cause harm. > **Reference:** Harrison's Principles of Internal Medicine, 21st ed., Ch. 445 (Ischemic Stroke); ACCORD Study Group, NEJM 2008; ADA Standards of Medical Care in Diabetes 2024.